MedTrace Logo

Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)

NCT00636558 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2019-07-01

No results posted yet for this study

Summary

Coxsackie A21 (CVA21) virus is to be administered by IV infusion to patients with Stage 4 melanoma, prostate and breast cancer. This is a dose escalation, safety study.

Conditions

Interventions

DRUG

CVA21

IV infusion, dose escalation of one or two infusions of escalating strength

Sponsors & Collaborators

  • Viralytics

    lead INDUSTRY

Principal Investigators

  • Boris Chern, MD · Redcliffe Hospital, Brisbane, Qld., Australia

  • Winston Liauw, MD · St George Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2012-01-12
Completion
2012-01-12

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00636558 on ClinicalTrials.gov